Chronic diseases—according to the UN, cardiovascular and kidney diseases are the scourge of humanity in the 21st century!*

The Problem:

Chronic diseases are often recognized far too late—only after significant organ damage has occurred! By then, the disease can no longer be stopped.

Chronic cardiovascular and kidney diseases lead to a permanent reduction in quality of life, shorten life expectancy by up to 20 years, and are increasingly affecting younger people, such as those with diabetes. Chronic kidney disease, for instance, increases the risk of cardiovascular disease by up to 20 times.

The Dilemma:

Chronic diseases, often recognized too late, with underlying conditions such as endothelial damage (inner lining of blood vessels) and fibrosis (scarring after inflammation or injury), lay the groundwork for pandemics like COVID-19.

*World Health Assembly, 42nd. (‎1989)‎. Prevention and control of cardiovascular diseases and other chronic noncommunicable diseases.

Breakthrough Improvement:

Check-up test from protexam

Early detection of chronic cardiovascular disease and chronic kidney disease using Protexam's check-up test can significantly reduce disease-related downtime because:

• Chronic diseases initially develop at the molecular and cellular levels, regulated exclusively by proteins.
• These diseases are symptomless and painless in their early stages, often leading to late diagnosis—typically only after massive organ damage has occurred.
• Medications are most effective when targeting proteins during the early stages of the disease.
• Drugs act on specific target proteins, which can only be identified through proteome analysis, enabling the assignment of the most effective treatments for each individual patient.

Once cells and organs have been irreparably damaged, the progressive loss of organ function cannot be halted, only slowed.

This is a breakthrough that only proteome analysis can achieve—worldwide, uniquely, and for the first time!

Study evidence and publications since 2002

Since 2002, the R&D facility mosaiques diagnostics GmbH has conducted more than 100 clinical, evidence-based studies in collaboration with over 1,200 leading physicians and scientists from 85 university hospitals worldwide. These studies have led to over 400 peer-reviewed publications, many funded by the European Commission and featured in high-impact scientific journals.

Extensive research across a broad spectrum of chronic diseases has consistently demonstrated the significant clinical benefits of mosaiques' proteomic analysis technology. These studies provide compelling evidence of the technology’s effectiveness in early disease detection, individualized treatment strategies, and improved patient outcomes. This body of work has firmly established Mosaiques' technology as a groundbreaking tool in precision medicine, shaping the future of healthcare and offering new insights into the molecular mechanisms of various diseases.

The breadth of these publications highlights the global recognition and scientific credibility of mosaiques' approach, positioning it at the forefront of advancements in both diagnostics and personalized medicine.

Requesting the Heart and Kidney Check-Up Test

Simple - Efficient - Fast

• The proteome test can be easily ordered via email or telephone.
• A sampling kit will be sent to you, allowing the sample to be conveniently collected at home.
• The shipment of the urine sample to the laboratory will be organized for you.
• The measurement and evaluation of the proteome analysis are typically sent to the designated doctor within one week.

Please email us to let us know how many tests you require for your employees.

Unique, proprietary database and AI

Mosaiques has developed a unique, highly specialized proteome database derived from over 100 clinical studies involving more than 85,000 samples. This database includes detailed case histories and tracks disease progression through millions of individual protein measurements. This extensive dataset, combined with the robustness and validity of Mosaiques' proprietary technology, provides the foundation for identifying biomarkers associated with various diseases.



Proteomic analysis results are compared against disease-specific proteomes validated in clinical studies using AI-driven analysis powered by Mosaiques' comprehensive proteomic database. These results are presented in a 3D format, forming the basis for accurate diagnoses and personalized treatments tailored to each individual's unique proteome.